Symbollon Pharmaceuticals Inc. (SYMBA)
Interview with: Paul Desjourdy, President, CFO and COO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their development and
commercialization of proprietary drugs based on its molecular iodine technology
with their IoGen™ already in clinical trials as a potential
treatment for moderate to severe cyclic pain and tenderness (clinical mastalgia)
associated with fibrocystic breast disease (FBD. |
Cover Story
CEOCFO
Interview Index
CEOCFO
Current Issue
Cover Story
Archives
Future Features
Analyst Interviews
Corporate
Financials
Archived Interviews
About CEOCFOinterviews.com
Contact
& Ordering |
This is a printer friendly page!
With
no safe and effective products on the market for treating fibrocystic
breast disease Symbollon Pharmaceuticals is taking the lead as it enters the final stages
of testing for its IoGen™ drug
Healthcare
Biotech and Drugs
(SYMBA-OTC)
Symbollon Pharmaceuticals Inc.
Paul Desjourdy
President, CFO and COO
Interview conducted by:
Lynn Fosse
Senior Editor
CEOCFOinterviews.com
June 2004
Instant Access:
To view a copy of this highly informative interview, left click here: ViewSYMBA
disclaimer
|
